NeuroNOS
Biopharmaceutical company developing small-molecule, brain-penetrant therapies that modulate neuronal nitric oxide (NO) signaling for neurodevelopmental and neurodegenerative disorders (notably autism spectrum disorder, Alzheimer’s disease, and glioblastoma). The company conducts preclinical validation in rodent and human stem-cell models, is advancing formulation and manufacturing partnerships, is preparing IND-enabling studies and first-in-human trials, and collaborates with academic technology transfer and research partners.
Industries
Nr. of Employees
small (1-50)
NeuroNOS
Investor relations contact (Boston / LifeSci Advisors)
Products
Lead small-molecule CNS-penetrant therapeutic candidates (injectable and oral formulations)
Investigational small molecules designed to modulate neuronal nitric oxide production in the brain; being advanced through preclinical validation, formulation development (subcutaneous and prospective oral), and IND-enabling work.
Lead small-molecule CNS-penetrant therapeutic candidates (injectable and oral formulations)
Investigational small molecules designed to modulate neuronal nitric oxide production in the brain; being advanced through preclinical validation, formulation development (subcutaneous and prospective oral), and IND-enabling work.
Expertise Areas
- NO/nNOS-targeted neurotherapeutics
- Preclinical behavioral pharmacology
- Translational stem cell modeling
- Proteomics and nitrosylation biology
Key Technologies
- nNOS inhibition (nitric oxide modulation)
- Small-molecule CNS-penetrant drug design
- Rodent behavioral assays (elevated plus maze, novel object recognition, sociability assays)
- Patient-derived stem cell neuronal models
News & Updates
U.S. FDA granted Orphan Drug Designation to the company's lead investigational therapy for Phelan-McDermid Syndrome; company planning first-in-human ASD trials in 2026.
Peer-reviewed research by the company's CSO reporting shared NO-related molecular mechanisms in Alzheimer’s disease mouse models and suggesting NO modulation as a therapeutic strategy.
Raised initial $2.0 million in private equity to accelerate preclinical and formulation development; engaged a U.S.-based contract manufacturer.
Appointments of Prof. Roger D. Kornberg and Prof. Dan Shechtman to the Scientific Advisory Board to provide molecular and structural biology expertise.
U.S. FDA granted Orphan Drug Designation to a lead investigational therapy for glioblastoma, expanding the company’s oncology-focused development.
Publications include studies on nitric oxide’s role in ASD, proteomics revealing mTOR alterations, and preclinical evaluations of nNOS inhibitors and formulations.
U.S. FDA granted Orphan Drug Designation to the company's lead investigational therapy for Phelan-McDermid Syndrome; company planning first-in-human ASD trials in 2026.
Peer-reviewed research by the company's CSO reporting shared NO-related molecular mechanisms in Alzheimer’s disease mouse models and suggesting NO modulation as a therapeutic strategy.
Raised initial $2.0 million in private equity to accelerate preclinical and formulation development; engaged a U.S.-based contract manufacturer.
Appointments of Prof. Roger D. Kornberg and Prof. Dan Shechtman to the Scientific Advisory Board to provide molecular and structural biology expertise.
U.S. FDA granted Orphan Drug Designation to a lead investigational therapy for glioblastoma, expanding the company’s oncology-focused development.
Publications include studies on nitric oxide’s role in ASD, proteomics revealing mTOR alterations, and preclinical evaluations of nNOS inhibitors and formulations.